ExoDx - Prostate Test
The only exosome-based test that provides unique, actionable intelligence to help you decide if biopsy is necessary; independent of PSA and other standard of care (SOC) features. Connect with a representative in your area for more information today.
- 91 % Negative Predictive Value for the ExoDx Prostate Test
- 92 % Sensitivity for the ExoDx Prostate Test
- 92 % Improved Patient Compliance to Physician Recommendation
- 30 % More HGPCa Identified vs. SOC Alone
The ExoDx™ Prostate Test is a simple, non-DRE, urine-based, liquid biopsy test indicated for men 50 years of age and older with a prostate-specific antigen (PSA) 2-10ng/mL, or PSA in the “gray zone”, considering an initial biopsy. The ExoDx Prostate test returns a risk score that determines a patient’s risk of clinically significant prostate cancer (Gleason Score ≥7) on prostate biopsy. A score above the validated cut-point of 15.6 is associated with an increased likelihood of GS≥7 PCa on a biopsy and a score below the cut-point of 15.6 is associated with a decreased likelihood of GS≥7 PCa. This test can help reassure a patient to avoid a prostate biopsy or improve patient compliance with physician recommendation.
The clinical validity of ExoDx is supported by multiple peer-reviewed publications and presentations, representing approximately 5000 patients from 40 academic and community urology clinics in the US.
The ExoDx Test has been clinically validated to risk stratify clinically significant (Gleason Score ≥7) prostate cancer from low grade prostate cancer (Gleason Score 6) and benign disease. A patient-specific individual risk score is calculated based on a proprietary algorithm that combines the weighted expression of a three-gene signature associated with clinically significant prostate cancer (PCA3, SPDEF, ERG) directly from urinary exosomal RNA.